Skin testing and drug provocation tests ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Skin testing and drug provocation tests in epidermal necrolysis: a French experience.
Auteur(s) :
Roux, Camille [Auteur]
Hôpital Henri Mondor
Ben Said, Benoit [Auteur]
Service d'immunologie [Centre Hospitalier Lyon Sud - HCL]
Milpied, Brigitte [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Bernier, Claire [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Staumont, delphine [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Dezoteux, Frédéric [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Soria, Angèle [Auteur]
CHU Tenon [AP-HP]
Barbaud, Annick [Auteur]
CHU Tenon [AP-HP]
Valeyrie-Allanore, Laurence [Auteur]
Tétart, Florence [Auteur]
CHU Rouen
Bellon, Nathalia [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Lebrun-Vignes, Bénédicte [Auteur]
Epidemiology in Dermatology and Evaluation in Therapeutics [EpiDermE]
Gener, Gwendeline [Auteur]
CHU Henri Mondor [Créteil]
Paul, Muriel [Auteur]
Hôpital Henri Mondor
Ingen-Housz-Oro, Saskia [Auteur]
Epidemiology in Dermatology and Evaluation in Therapeutics [EpiDermE]
Assier, Haudrey [Auteur]
Service de dermatologie [Mondor]
Hôpital Henri Mondor
Ben Said, Benoit [Auteur]
Service d'immunologie [Centre Hospitalier Lyon Sud - HCL]
Milpied, Brigitte [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Bernier, Claire [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Staumont, delphine [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Dezoteux, Frédéric [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Soria, Angèle [Auteur]
CHU Tenon [AP-HP]
Barbaud, Annick [Auteur]
CHU Tenon [AP-HP]
Valeyrie-Allanore, Laurence [Auteur]
Tétart, Florence [Auteur]
CHU Rouen
Bellon, Nathalia [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Lebrun-Vignes, Bénédicte [Auteur]
Epidemiology in Dermatology and Evaluation in Therapeutics [EpiDermE]
Gener, Gwendeline [Auteur]
CHU Henri Mondor [Créteil]
Paul, Muriel [Auteur]
Hôpital Henri Mondor
Ingen-Housz-Oro, Saskia [Auteur]
Epidemiology in Dermatology and Evaluation in Therapeutics [EpiDermE]
Assier, Haudrey [Auteur]
Service de dermatologie [Mondor]
Titre de la revue :
The Journal of Allergy and Clinical Immunology: In Practice
Nom court de la revue :
J Allergy Clin Immunol Pract
Numéro :
10
Pagination :
3252-3261
Date de publication :
2022-07-27
ISSN :
2213-2201
Mot(s)-clé(s) en anglais :
Epidermal necrolysis
Stevens-Johnson syndrome
Lyell syndrome
Toxic epidermal necrolysis
Patch tests
Intradermal tests
Drug provocation tests
Cutaneous adverse drug reaction
Skin tests
Stevens-Johnson syndrome
Lyell syndrome
Toxic epidermal necrolysis
Patch tests
Intradermal tests
Drug provocation tests
Cutaneous adverse drug reaction
Skin tests
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background
There are limited data on the use of skin testing, other than patch testing, and challenges in the evaluation of epidermal necrolysis (EN), including Stevens-Johnson syndrome and toxic epidermal necrolysis.
...
Lire la suite >Background There are limited data on the use of skin testing, other than patch testing, and challenges in the evaluation of epidermal necrolysis (EN), including Stevens-Johnson syndrome and toxic epidermal necrolysis. Objective To report a French multicenter experience in skin testing and challenges in EN, and investigate the factors associated with tests’ positivity. Methods All patients who were evaluated by patch tests (PTs), skin prick tests, intradermal tests (IDTs), or drug provocation tests (DPTs) for EN between 2010 and 2020 were retrospectively included through 2 French drug reaction networks. Results In total, 113 patients were included from 8 centers. Median (interquartile range) time from EN to hypersensitivity workup was 7.9 months (5.1–15 months). All patients had PTs, 17 (15%) had skin prick tests or IDTs with delayed readings and 32 (28.3%) had DPTs. One mild reaction occurred after a DPT. Overall, 22 patients (19.5%) had positive PTs, and the only factors associated with positivity were Algorithm of Drug Causality for Epidermal Necrolysis (ALDEN) score and drug class. Only 1 IDT was positive but considered irrelevant. The DPTs were never performed to prove responsibility of a highly suspected drug but were used to confirm current tolerance of needed medications. Conclusions Allergological workup in EN, performed by specialists involved in EN, seems safe. Skin tests, although of limited sensitivity, can be helpful for considering the reintroduction of essential drugs according to a benefit-to-risk decision. We propose an algorithm for approaching hypersensitivity testing in patients with EN, to be adapted to each patient.Lire moins >
Lire la suite >Background There are limited data on the use of skin testing, other than patch testing, and challenges in the evaluation of epidermal necrolysis (EN), including Stevens-Johnson syndrome and toxic epidermal necrolysis. Objective To report a French multicenter experience in skin testing and challenges in EN, and investigate the factors associated with tests’ positivity. Methods All patients who were evaluated by patch tests (PTs), skin prick tests, intradermal tests (IDTs), or drug provocation tests (DPTs) for EN between 2010 and 2020 were retrospectively included through 2 French drug reaction networks. Results In total, 113 patients were included from 8 centers. Median (interquartile range) time from EN to hypersensitivity workup was 7.9 months (5.1–15 months). All patients had PTs, 17 (15%) had skin prick tests or IDTs with delayed readings and 32 (28.3%) had DPTs. One mild reaction occurred after a DPT. Overall, 22 patients (19.5%) had positive PTs, and the only factors associated with positivity were Algorithm of Drug Causality for Epidermal Necrolysis (ALDEN) score and drug class. Only 1 IDT was positive but considered irrelevant. The DPTs were never performed to prove responsibility of a highly suspected drug but were used to confirm current tolerance of needed medications. Conclusions Allergological workup in EN, performed by specialists involved in EN, seems safe. Skin tests, although of limited sensitivity, can be helpful for considering the reintroduction of essential drugs according to a benefit-to-risk decision. We propose an algorithm for approaching hypersensitivity testing in patients with EN, to be adapted to each patient.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Date de dépôt :
2024-01-12T01:00:14Z
2024-03-26T08:45:26Z
2024-03-26T08:45:26Z